T. Rowe Price Associates’s Adamas Pharmaceuticals, Inc. ADMS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-26,000
| Closed | -$128K | – | 3093 |
|
|
2021
Q3 | $128K | Sell |
26,000
-7,700
| -23% | -$37.9K | ﹤0.01% | 2794 |
|
|
2021
Q2 | $178K | Sell |
33,700
-30,000
| -47% | -$158K | ﹤0.01% | 2749 |
|
|
2021
Q1 | $306K | Hold |
63,700
| – | – | ﹤0.01% | 2556 |
|
|
2020
Q4 | $276K | Hold |
63,700
| – | – | ﹤0.01% | 2449 |
|
|
2020
Q3 | $262K | Sell |
63,700
-20,600
| -24% | -$84.7K | ﹤0.01% | 2335 |
|
|
2020
Q2 | $216K | Sell |
84,300
-1,439
| -2% | -$3.69K | ﹤0.01% | 2338 |
|
|
2020
Q1 | $248K | Buy |
85,739
+16,800
| +24% | +$48.6K | ﹤0.01% | 2249 |
|
|
2019
Q4 | $261K | Buy |
68,939
+10,011
| +17% | +$37.9K | ﹤0.01% | 2349 |
|
|
2019
Q3 | $301K | Buy |
58,928
+131
| +0.2% | +$669 | ﹤0.01% | 2272 |
|
|
2019
Q2 | $365K | Buy |
58,797
+46,200
| +367% | +$287K | ﹤0.01% | 2235 |
|
|
2019
Q1 | $90K | Buy |
12,597
+100
| +0.8% | +$714 | ﹤0.01% | 2470 |
|
|
2018
Q4 | $107K | Sell |
12,497
-4,164
| -25% | -$35.7K | ﹤0.01% | 2471 |
|
|
2018
Q3 | $334K | Buy |
16,661
+129
| +0.8% | +$2.59K | ﹤0.01% | 2306 |
|
|
2018
Q2 | $427K | Buy |
+16,532
| New | +$427K | ﹤0.01% | 2201 |
|